Participants in this phase 3 trial saw remarkable outcomes at 80 weeks: a weight loss averaging 28.3% on the 12 mg dose
Acknowledgements The authors would like to thank Henrik Kim Nielsen, Jens Heisterberg, and Karen Hauda (Novo Nordisk A/S, Denmark), and Gina MacNeil (Novo Nordisk Inc, United States) for review of, and input to, the manuscript, as well as Tina stergaard, Sisse Lakner Schmidt, and Michala Cronberg (Novo Nordisk A/S, Denmark) for help with physical stability analyses
How does the Precision Peptide Genetic Test help me choose between semaglutide injection and oral
While semaglutide is not a miracle drug, it offers a powerful tool for individuals struggling with weight-related health challenges
Cheng D, Yang S, Zhao X, et al
Choosing between them depends on factors such as treatment goals, side effect profile, availability, and individual response, which is why professional guidance is essential